Company DescriptionBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity. It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

How the Company Makes Money

BetterLife Pharma Financial Statement Overview

Summary

BetterLife Pharma is facing severe financial challenges with no revenue generation, substantial losses, negative equity, and unsustainable cash flows. The company's financial health is weak, with high leverage and dependency on financing activities to maintain liquidity.

Income Statement

Very Negative

BetterLife Pharma has not generated any revenue over the past years, leading to negative gross profit and net income. The company shows significant losses, with high negative EBIT and EBITDA margins. The absence of revenue growth and persistent losses highlight financial challenges.

Balance Sheet

Very Negative

The company has negative stockholders' equity, indicating liabilities exceed assets, which is a significant financial concern. The debt-to-equity ratio cannot be computed due to negative equity, but substantial debt levels pose a high leverage risk. The financial structure is unstable, with liabilities consistently rising.

Cash Flow

Very Negative

Operating cash flows are negative, reflecting cash outflows from operations. Free cash flow is also negative, indicating financial strain in sustaining operations. The financing activities seem to be the primary source of liquidity, but the overall cash flow position is unsustainable.

TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Breakdown
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	-18.43K	-18.44K	―	―
	EBIT
-5.02M	-3.24M	-9.46M	-10.21M	-7.92M	-18.73M
	EBITDA
-2.10M	-3.19M	-9.24M	-9.95M	-7.83M	-17.40M
	Net Income Common Stockholders
-4.88M	-2.89M	-9.02M	-12.16M	-36.35M	-19.59M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
37.38K	37.38K	8.31K	173.51K	154.72K	2.68M
	Total Assets
324.75K	324.75K	74.73K	1.16M	1.34M	8.25M
	Total Debt
245.23K	1.47M	1.19M	1.40M	500.00K	4.70M
	Net Debt
207.85K	1.43M	1.18M	1.22M	345.28K	2.02M
	Total Liabilities
8.02M	8.02M	7.61M	5.04M	5.95M	5.59M
	Stockholders Equity
-10.81M	-10.81M	-10.73M	-3.88M	-4.61M	2.66M
Cash Flow		Free Cash Flow
-2.51M	-2.47M	-1.50M	-11.20M	-7.26M	-8.42M
	Operating Cash Flow
-2.51M	-2.47M	-1.50M	-11.20M	-7.16M	-7.88M
	Investing Cash Flow
0.00	0.00	165.04K	―	-71.55K	-1.14M
	Financing Cash Flow
2.58M	2.50M	1.34M	11.23M	4.09M	12.23M

BetterLife Pharma Risk Analysis

BetterLife Pharma disclosed 20 risk factors in its most recent earnings report. BetterLife Pharma reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

BetterLife Pharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BETRF		$9.03M	―		―	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
KNE	43 Neutral	C$8.29M	―	-813.02%	―	―	―
BLAB	42 Neutral	C$9.74M	―	-175.45%	―	-3.93%	-575.24%
HEM	41 Neutral	C$16.71M	―	34.47%	―	―	43.45%
RVX		C$11.37M	―		―	―	―
TBP		$8.47M	―		―	―	―

* Healthcare Sector Average

Performance Comparison

BETRF

BetterLife Pharma

0.06

-0.03

-33.33%

TSE:HEM

Hemostemix

0.12

0.06

100.00%

TSE:KNE

Kane Biotech

0.05

-0.08

-61.54%

TSE:BLAB

Britannia Life Sciences Inc

0.06

0.00

0.00%

TSE:RVX

Resverlogix

0.04

-0.01

-20.00%

TSE:TBP

Tetra Bio-Pharma

0.02

0.00

0.00%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.